Lineage Cell Therapeutics, Inc. (TLV: LCTX)
Israel
· Delayed Price · Currency is ILS · Price in ILA317.90
-6.10 (-1.88%)
Oct 15, 2024, 5:24 PM IDT
Lineage Cell Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -24.19 | -21.49 | -26.27 | -43.02 | -20.65 | -11.71 | Upgrade
|
| Depreciation & Amortization | 0.67 | 0.69 | 0.73 | 0.87 | 2.11 | 3.13 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -0.01 | 0.02 | -0.02 | 0.27 | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.18 | -0.5 | 1.69 | -3.73 | -0.78 | -14.81 | Upgrade
|
| Stock-Based Compensation | 4.76 | 4.64 | 4.29 | 3.72 | 2.35 | 3.58 | Upgrade
|
| Other Operating Activities | 0.35 | -1.11 | 2.01 | -2.28 | -4.03 | -10.2 | Upgrade
|
| Change in Accounts Receivable | 0.21 | -0.45 | 50.31 | -0.86 | 0.29 | 0.47 | Upgrade
|
| Change in Accounts Payable | 0.4 | -2.3 | -18.7 | 21.65 | 0.31 | -2.89 | Upgrade
|
| Change in Unearned Revenue | -4.38 | -7.65 | -13.35 | 0.38 | 0.13 | - | Upgrade
|
| Change in Other Net Operating Assets | 0.37 | -0.42 | 0.45 | -0.07 | 0.57 | 0.33 | Upgrade
|
| Operating Cash Flow | -22.02 | -28.57 | 1.06 | -23.56 | -19.75 | -31.95 | Upgrade
|
| Capital Expenditures | -0.32 | -0.67 | -0.41 | -0.34 | -0.06 | -0.44 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | - | 0.02 | 0.08 | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | 3.12 | Upgrade
|
| Divestitures | - | - | - | 0.02 | 2.12 | 3.48 | Upgrade
|
| Investment in Securities | 3.35 | 47.12 | -45.75 | 10.06 | 10.94 | 10.74 | Upgrade
|
| Other Investing Activities | - | - | - | - | 0.02 | -0.02 | Upgrade
|
| Investing Cash Flow | 3.03 | 46.45 | -46.16 | 9.75 | 13.04 | 16.96 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 0.52 | - | Upgrade
|
| Total Debt Issued | - | - | - | - | 0.52 | - | Upgrade
|
| Long-Term Debt Repaid | - | -0.05 | -0.03 | -0.02 | -0.03 | -0.1 | Upgrade
|
| Net Debt Issued (Repaid) | -0.05 | -0.05 | -0.03 | -0.02 | 0.5 | -0.1 | Upgrade
|
| Issuance of Common Stock | 15.13 | 6.71 | 0.8 | 38.11 | 5.13 | 0.1 | Upgrade
|
| Repurchase of Common Stock | -0.02 | -0.04 | -0.02 | -0.05 | -0.03 | -0.11 | Upgrade
|
| Other Financing Activities | -0.14 | -0.2 | 0.89 | -1.1 | 24.27 | 0.72 | Upgrade
|
| Financing Cash Flow | 14.92 | 6.42 | 1.63 | 36.93 | 29.87 | 0.62 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.22 | -0.25 | -0.87 | -0.02 | -0.06 | 0.07 | Upgrade
|
| Net Cash Flow | -4.28 | 24.06 | -44.34 | 23.09 | 23.09 | -14.3 | Upgrade
|
| Free Cash Flow | -22.33 | -29.24 | 0.65 | -23.9 | -19.82 | -32.39 | Upgrade
|
| Free Cash Flow Margin | -361.02% | -326.89% | 4.39% | -550.59% | -1085.27% | -921.39% | Upgrade
|
| Free Cash Flow Per Share | -0.12 | -0.17 | 0.00 | -0.15 | -0.13 | -0.22 | Upgrade
|
| Cash Interest Paid | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | Upgrade
|
| Levered Free Cash Flow | -8.91 | -10.37 | 13.34 | -37.46 | 13.44 | -37.26 | Upgrade
|
| Unlevered Free Cash Flow | -8.91 | -10.37 | 13.34 | -37.46 | 13.44 | -37.26 | Upgrade
|
| Change in Net Working Capital | 0.23 | 1.78 | -22.81 | 10.95 | -25.58 | 22.42 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.